NIKKEI 225
38,214.90 +140.92 (+0.37%) HANG SENG
18,858.27 +320.46 (+1.73%) CRUDE OIL
79.79 +0.53 (+0.67%) GOLD FUTURES
2,359.70 +19.40 (+0.83%) DOW
39,387.76 +331.36 (+0.85%) Bitcoin GBP
50,222.11 +925.46 (+1.88%)
Cytek Biosciences, Inc. (CTKB)
After hours:
- GuruFocus.com
Cytek Biosciences Inc (CTKB) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth ...
Explore how Cytek Biosciences Inc navigates through revenue growth and operational expansions while addressing financial hurdles in the first quarter of 2024.
- Zacks
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Tops Revenue Estimates
Cytek Biosciences (CTKB) delivered earnings and revenue surprises of 80% and 2.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Cytek Biosciences Reports First Quarter 2024 Financial Results
FREMONT, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights Total revenue was $44.9 million, representing a 21% increase over the corresponding period of 2023 Organic revenue was $37.3 million, representing an increase of 11% compared to the first quarter of 2023First quarter revenue from the prod
